SGLT2 Inhibitors: Unreal Primary Prevention? | Latest News RSS feed

SGLT2 Inhibitors: Unreal Primary Prevention? - Latest News


Heart failure: SGLT2 inhibitors and heart failure — clinical implications

The DECLARE trial might indicate the effect of SGLT2 inhibitors on primary prevention of cardiovascular disease, hospitalization for HF, and cardiovascular death in this population. The EMPA-REG OUTCOME trial has triggered multiple research questions about ... read more

Many primary care docs may miss prediabetes

(HealthDay News) -- Most primary care doctors can't identify all 11 risk factors ... and rare but dangerous complication A new class of type 2 diabetes drugs called SGLT2 inhibitors could increase the risk of a rare, life-threatening complication of ... read more

New Method to Deliver Glucose to Cancer Cells Could Prove Key to Defeating Deadly Cancers

Cancer cells require high amounts of glucose to grow and survive, and long-standing research has established passive glucose transporters (or GLUTS) as the primary delivery ... it provides strong evidence that SGLT2 inhibitors, such as those currently ... read more

Looking for another news?


Boehringer Ingelheim, Lilly ink academic collaboration with University of Oxford to investigate effects of empagliflozin in people with CKD

The primary outcome of the study is to assess the effect of ... the largest clinical development programme of an SGLT2 inhibitor. “We are delighted to partner with such a prestigious academic institution as Oxford University. The scientists at Oxford ... read more


Repatha's Next Challenge Is Expectations

Both will have much to prove, as payers are eager to see whether a profound reduction of LDL can translate into prevention of cardiovascular complications ... The anti-diabetic SGLT-2 drugs have earned a prominent place in a late-breaking presentation ... read more

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

"The AWARD-10 results suggest that the combination of once-weekly Trulicity and an SGLT-2 inhibitor shows significant promise in helping more people with type 2 diabetes reach their treatment goals." At the study's primary endpoint of 24 weeks, both ... read more

Form 6-K ASTRAZENECA PLC For: Apr 29

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F __ Indicate by check mark if the registrant is submitting the Form 6-K in paper as ... read more

Upcoming Conversation With An Expert: Understanding The Potential Of Lexicon's Sotagliflozin As A Novel Treatment For Diabetes

Sotagliflozin’s inTandem3 Phase 3 trial successfully met all primary and secondary ... If other SLGT-2 inhibitors close the door for glucose absorption, sotagliflozin closes the windows as well. This is crucial because while SGLT-2 is responsible for ... read more

Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies

an investigational oral SGLT-2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes, met their primary endpoints. In the studies, both doses of ertugliflozin tested (5 mg and 15 mg daily) achieved statistically ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us